Abstract: Disclosed is a binding protein having at least two protein functional regions, the binding protein comprising a protein functional region A and a protein functional region B; the protein functional region A and the protein functional region B target different antigens or epitopes, the protein functional region A is a Fab or a scFv structure, the protein functional region B is a VH structure, and there are one or more of each of the protein functional region A and the protein functional region B. A multi-specific binding protein has a smaller molecular weight, fewer polypeptide chains, and a simpler structure. By means of different structure types, relative positions, binding valence and other parameters, the functional activities for different targets can be adjusted, and then different combinations of activities can be designed so as to meet the needs of different dose combinations of clinical combinations.

Abstract: The present invention provides a binding protein and use thereof, wherein the binding protein comprises a first protein functional region binding to a targeting moiety of an antigen on a target cell, and a second protein functional region binding to an effector moiety of an antigen on an immune effector cell; and the binding protein is selected from the following structure: the first protein functional region is of a Fab structure, the second protein functional region is of a VH structure or a Fab structure, and the first protein functional region and the second protein functional region are arranged sequentially from the N-terminus to the C-terminus of the binding protein. The binding protein can bring the immune effector cell and the specific target cell together, efficiently and selectively activate the immune effector cell in a microenvironment of the specific target cell, further enhance immune responses, and reduce toxic and side effects caused by non-specific activation of peripheral immune cells.

Abstract: An OX40-targeted antibody or an antigen binding fragment thereof. The OX40-targeted antibody comprises a VH. The VH comprises the following CDRs or mutants thereof: a VH CDR1 as shown in an amino acid sequence of SEQ ID NO: 10, a VH CDR2 as shown in an amino acid sequence of SEQ ID NO: 44, and/or a VH CDR3 as shown in an amino acid sequence of SEQ ID NO: 86, SEQ ID NO: 84, or SEQ ID NO: 89. Also disclosed is a preparation method, an application, and a double-antibody comprising same. The antibody or the antigen binding fragment thereof can specifically bind to OX40, promote larger activation of NF-Kb, activate OX40 pathways in vitro, and induce activation of T cell function. The double-antibody can identify tumor target TAA, can bind to OX40 on the T cell, and can recruit and activate T cells near tumor cells to kill tumor cells.

Abstract: Provided is a binding protein, which comprises a protein functional region A and a protein functional region B, both of which target different antigens or different epitopes of antigens. The protein functional region A is Fab; the protein functional region B is VH; and the binding protein also comprises an Fc homodimer. There are two of both the protein functional region A and the protein functional region B. The binding protein has a left-right symmetrical structure. The binding protein consists of the protein functional region A, the protein functional region B and Fc in sequence from the N-terminus to the C-terminus, wherein the protein functional region A and the protein functional region B are connected by means of L1, and the protein functional region B is connected to the Fc by means of L2. The binding protein has a relatively small molecular mass, few polypeptide chains and a simpler structure. The protein has a versatile structure and may be applied to a variety of different target combinations.

Abstract: An electrically conductive multilayer film for providing an electrical path between two conductive surfaces includes a plastic backing layer, an electrically conductive layer disposed on a first side of the plastic backing layer, and a recovery layer disposed on an opposite second side of the plastic backing layer. An average thickness of the multilayer film is less than about 100 microns. A hollow gasket can be formed from the multilayer film by winding or bending the multilayer film into a flexible hollow closed loop. When the multilayer film is wound to form a flexible closed loop having an outside diameter of no more than about 7 mm with the conductive layer forming an outside layer of the loop, a resistance of the closed loop across a diameter of the closed loop remains less than about 2? when the loop is compressed across the diameter by at least 20%.

Abstract: A reactor, comprising: a support; a coil wound on an outer surface of the support and including a plurality of coil segments electrically connected in sequence; and at least one first insulating separator disposed on the outer surface of the support and separating the outer surface of the support into a plurality of regions, in which the plurality of coil segments is respectively arranged.

Abstract: The present invention discloses a 4-1BB-binding protein and use thereof. The 4-1BB-binding protein comprises a heavy chain variable region, wherein the heavy chain variable region comprises HCDR1, HCDR2 and HCDR3, wherein the HCDR1 comprises a sequence as set forth in SEQ ID NO: 15 or a variant 1 thereof, or SEQ ID NO: 16; the HCDR2 comprises a sequence selected from SEQ ID NO: 60 or a variant 2 thereof, and SEQ ID NO: 50 or a variant 4 thereof; the HCDR3 comprises a sequence as set forth in SEQ ID NO: 103 or a variant 3 thereof, SEQ ID NO: 333 or a variant 5 thereof, SEQ ID NO: 110, SEQ ID NO: 111, SEQ ID NO: 116, SEQ ID NO: 326, SEQ ID NO: 331, SEQ ID NO: 334 or SEQ ID NO: 96. The 4-1BB-binding protein of the present invention is a fully human antibody having the binding activity to human 4-1BB and cynomolgus monkey 4-1BB. Some 4-1BB-binding proteins are only half the size of conventional IgG antibodies; they can be well used for bispecific antibodies.

Abstract: Provided are a bispecific antibody and use thereof. The bispecific antibody comprises a B7-H4-targeting antigen-binding domain and a 4-1BB-targeting antigen-binding domain. The bispecific antibody has one or two or three sites for binding to 4-1BB, along with a novel fully human B7-H4 antibody. The bispecific antibody specifically binds to tumor cells by targeting B7-H4, reducing toxicity induced by 4-1BB activation. In addition, the bispecific antibody of the present invention comprises a human Fc fragment, and thus retains the binding of Fc to FcRn and has a longer half-life.

Abstract: A method, system and apparatus for forwarding data in a virtual network, an electronic device, a storage medium and a computer program product are provided. The method includes: determining, in a process of managing virtual private cloud networks through a central control node, all forwarding rules for nodes in the virtual private cloud networks; synchronizing the forwarding rules in a virtual routing cluster, and determining target forwarding rules corresponding to each virtual private cloud network from the forwarding rules; and through a virtual switch in each virtual private cloud network, learning the target forwarding rules corresponding to the virtual private cloud network to which the virtual switch belongs, and performing data forwarding based on the learned target forwarding rules.

Abstract: The present invention relates to a fibrotic disease mechanism, and a preventive/therapeutic drug and method therefor. The present invention can improve the level of cAMP by means of a PDE inhibitor such as dipyridamole to treat fibrotic diseases and inhibit the progress of fibrosis. The present invention further achieves anti-inflammatory and immune regulation effects, and achieves a therapeutic effect on all aspects of the occurrence and development of fibrosis.

Abstract: The present disclosure provides a method, apparatus and system for switching a virtual IP, relates to the field of artificial intelligence and particularly to cloud computing and cloud network technologies, and can be applied to intelligent cloud scenarios. A detailed implementation comprises: receiving a free ARP packet sent by a virtual machine to which a high-availability virtual IP is successfully switched; generating a first forwarding table of the high-availability virtual IP according to the free ARP packet; encapsulating the first forwarding table in a first UDP packet by VXLAN; and synchronizing the first UDP packet to another virtual router.

Abstract: The present invention relates to the use of a novel Lactobacillus brevis ProGA28 strain, deposited in the German Collection for Microorganisms and Cell Cultures (DSMZ) under the accession number DSM 33167 on May 28, 2019. The metabolites of Lactobacillus brevis ProGA28 have the ability to improve sleep quality, can effectively reduce the time of rapid eye movement in the sleep phase, can reduce time to fall asleep, can increase total sleep time, and can increase the ratio of low waves during sleep so that sleep disorders and related complications, such as anxiety and immune system diseases, are treated.

Abstract: Embodiments of the present disclosure relate to a method and apparatus for detecting traffic. The method includes: acquiring traffic information of at least two dimensions of a target IP; determining whether the traffic information of the at least two dimensions contains traffic information exceeding an abnormal traffic threshold of a corresponding dimension of the target IP; and in response to determining that the traffic information of the at least two dimensions contains the traffic information exceeding the abnormal traffic threshold of the corresponding dimension, determining that the traffic of the target IP is abnormal.

Abstract: The present invention relates to gastrointestinal diseases, such as non-infectious gastrointestinal diseases, including the immune mechanism of non-infectious gastrointestinal diseases in children, and the use of phosphodiesterase inhibitors and/or antiplatelet drugs in the treatment of gastrointestinal diseases such as non-infectious gastrointestinal diseases.

Abstract: An electrically conductive multilayer film for providing an electrical path between two conductive surfaces includes a plastic backing layer, an electrically conductive layer disposed on a first side of the plastic backing layer, and a recovery layer disposed on an opposite second side of the plastic backing layer. An average thickness of the multilayer film is less than about 100 microns. A hollow gasket can be formed from the multilayer film by winding or bending the multilayer film into a flexible hollow closed loop. When the multilayer film is wound to form a flexible closed loop having an outside diameter of no more than about 7 mm with the conductive layer forming an outside layer of the loop, a resistance of the closed loop across a diameter of the closed loop remains less than about 2? when the loop is compressed across the diameter by at least 20%.

Abstract: Methods for determining an in vitro release profile of peanut allergens in a sample are provided. Methods for determining one or more signatures of peanut allergens in a sample are provided.

Abstract: Methods for determining an in vitro release profile of peanut allergens in a sample are provided. Methods for determining one or more signatures of peanut allergens in a sample are provided.

Abstract: The present invention discloses a novel Lactobacillus brevis ProGA28, deposited in the German Collection for Microorganisms and Cell Cultures, the accession number is DSM 33167, and the deposit date is on 28 May, 2019. The metabolites of the novel Lactobacillus brevis ProGA28 has the ability to improve sleep quality, and can effectively reduce the time of rapid eye movement in sleep phase, reduce the number of falling asleep, increase the total sleep time, prolong the time of single falling asleep, and increase the ratio of low waves during sleep, so that it can achieve the effect of treating or improving sleep disorders and related complications, such as anxiety and immune system diseases.

Abstract: Embodiments of the present disclosure relate to a method and apparatus for detecting traffic. The method includes: acquiring traffic information of at least two dimensions of a target IP; determining whether the traffic information of the at least two dimensions contains traffic information exceeding an abnormal traffic threshold of a corresponding dimension of the target IP; and in response to determining that the traffic information of the at least two dimensions contains the traffic information exceeding the abnormal traffic threshold of the corresponding dimension, determining that the traffic of the target IP is abnormal.